The goal of this double-blind randomized controlled clinical trial is to determine the efficacy of the administration of magnesium chloride + vitamin D as an adjuvant in the treatment of post-Coronavirus Disease (COVID) syndrome. The participants will be integrated: a) Intervention group that will receive 1 g of magnesium chloride (equivalent to 300 mg of elemental magnesium) + 4000 IU of vitamin D once a day, for four months. b) Control group that will receive inert placebo for four months. The outcome variable will be the improvement of the post-COVID syndrome. At the beginning and end of the study, blood samples will be taken to determine serum levels of vitamin D, total magnesium, ionic magnesium, calcium, fasting glucose and lipid profile. The evaluation of the efficacy and safety of the proposed intervention will be carried out by establishing the differences between the intervention and control groups.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from Baseline Post-COVID syndrome symptoms at 4 months
Timeframe: First control date, and four months after treatment initiation.
Change from Baseline Post-COVID Functional Status at 4 months
Timeframe: First control date, and four months after treatment initiation.
Change from Baseline Serum vitamin D levels at 4 months
Timeframe: First control assessment, and four months after treatment initiation.
Change from Baseline Serum Magnesium levels at 4 months
Timeframe: First control assessment, and four months after treatment initiation.
Change from Baseline Mental State levels at 4 months
Timeframe: First control date, and four months after treatment initiation.
Change from Baseline Anxiety Symptoms at 4 months
Timeframe: First control date, and four months after treatment initiation.
Change from Baseline Depression Symptoms at 4 months
Timeframe: First control date, and four months after treatment initiation.
Change from Baseline Post-traumatic Stress Symptoms at 4 months
Timeframe: First control date, and four months after treatment initiation.
Change from Baseline Dyspnea Symptoms at 4 months
Timeframe: First control date, and four months after treatment initiation.